Artigos de Revisão

https://www.revistardp.org.br doi https://doi.org/10.25118/2763-9037.2024.v14.1309

Emerging trends in the treatment of obsessive-compulsive disorder: a literature review

Tendências emergentes no tratamento do transtorno obsessivo-compulsivo: uma revisão da literatura

Tendencias emergentes en el tratamiento del trastorno obsesivo-compulsivo: una revisión de la literatura

1 Kirolos Eskandar ORCID

Affiliation of authors: 1 [Main affiliation Diakonie-Klinik Mosbach, Mosbach, Baden Württemberg, Germany, Function [Physician], https://www.diakonie-klinik-mosbach.de/index.html]
Chief Editor responsible for the article: Marsal Sanches
Authors contributions according to the Taxonomia CRediT:
Eskandar K [1-3,5-14]
Disclosure of potential conflicts of interest: none
Funding: none
Approval Research Ethics Committee (REC): not applicable
Received on: 04/08/2024
Accepted on: 16/08/2024
Published on: 22/08/2024

How to cite: Eskandar K. Emerging trends in the treatment of obsessive-compulsive disorder: a literature review. Debates em Psiquiatria, Rio de Janeiro.2024;14:1-19.https://doi.org/10.25118/2763-9037.2024.v14.1309

ABSTRACT:
Obsessive-Compulsive Disorder (OCD) is a chronic and debilitating mental health condition characterized by persistent, intrusive thoughts and repetitive behaviors. Traditional treatments, including cognitive-behavioral therapy (CBT) and pharmacotherapy, have shown efficacy but are often limited by partial response and high relapse rates. This literature review examines the emerging trends in the treatment of OCD, highlighting

advancements in psychotherapy, novel pharmacological agents, neuromodulation techniques, digital interventions, genetic and biomarker research, and integrative therapies. Additionally, it explores tailored approaches for pediatric populations and discusses the future directions and challenges in the field. The review underscores the potential of these innovative treatments to enhance therapeutic outcomes and improve the quality of life for individuals with OCD.

Keywords: obsessive-compulsive disorder, OCD, cognitive-behavioral therapy, pharmacotherapy, neuromodulation, digital interventions, genetic research, integrative therapies, pediatric OCD

RESUMO:
O Transtorno Obsessivo-Compulsivo (TOC) é uma condição de saúde mental crônica e debilitante, caracterizada por pensamentos persistentes e intrusivos e comportamentos repetitivos. Os tratamentos tradicionais, incluindo a terapia cognitivo-comportamental (TCC) e a farmacoterapia, têm demonstrado eficácia, mas são frequentemente limitados pela resposta parcial e pelas altas taxas de recaída. Esta revisão da literatura examina as tendências emergentes no tratamento do TOC, destacando avanços na psicoterapia, novos agentes farmacológicos, técnicas de neuromodulação, intervenções digitais, pesquisa genética e de biomarcadores e terapias integrativas. Além disso, explora abordagens personalizadas para populações pediátricas e discute as futuras direções e desafios no campo. A revisão sublinha o potencial destes tratamentos inovadores para melhorar os resultados terapêuticos e melhorar a qualidade de vida dos indivíduos com TOC.

Palavras-chave: transtorno obsessivo-compulsivo, TOC, terapia cognitivo-comportamental, farmacoterapia, neuromodulação, intervenções digitais, pesquisa genética, terapias integrativas, TOC pediátrico

RESUMEN:
El trastorno obsesivo-compulsivo (TOC) es una afección de salud mental crónica y debilitante caracterizada por pensamientos persistentes e intrusivos y comportamientos repetitivos. Los tratamientos tradicionales, incluida la terapia cognitivo-conductual (TCC) y la farmacoterapia, han demostrado eficacia, pero a menudo están limitados por una respuesta parcial y altas tasas de recaída. Esta revisión de la literatura examina las tendencias emergentes en el tratamiento del TOC, destacando los avances

en psicoterapia, nuevos agentes farmacológicos, técnicas de neuromodulación, intervenciones digitales, investigación genética y de biomarcadores, y terapias integrativas. Además, explora enfoques personalizados para poblaciones pediátricas y analiza las direcciones y desafíos futuros en este campo. La revisión subraya el potencial de estos tratamientos innovadores para mejorar los resultados terapéuticos y mejorar la calidad de vida de las personas con TOC.

Palabras clave: trastorno obsesivo-compulsivo, TOC, terapia cognitivo-conductual, farmacoterapia, neuromodulación, intervenciones digitales, investigación genética, terapias integrativas, TOC pediátrico

Introduction

Obsessive-Compulsive Disorder (OCD) is a chronic psychiatric condition characterized by the presence of obsessions, compulsions, or both. Obsessions are persistent, unwanted thoughts, images, or urges that cause significant anxiety or distress. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to an obsession or according to rigid rules. These behaviors are often aimed at reducing the distress associated with the obsessions or preventing a feared event, although they are not connected in a realistic way to the prevention of that event or are clearly excessive [1, 2].

OCD is one of the most common mental disorders, affecting approximately 2-3% of the population globally. It typically begins in childhood, adolescence, or early adulthood and affects both genders equally, although women may be slightly more affected in adulthood [1, 3]. The World Health Organization ranks OCD among the top 10 most disabling conditions by lost income and decreased quality of life [4].

The importance of emerging treatments for OCD cannot be overstated. Traditional treatment options, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT), particularly exposure and response prevention (ERP), have been the mainstays of OCD management. However, many patients experience only partial relief, and some do not respond to these treatments at all. This necessitates the exploration of new and innovative approaches to treatment. Novel pharmacological treatments, advancements in psychotherapeutic techniques, and cutting-edge neuromodulation therapies like transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) hold promise for improving outcomes for those with treatment-resistant OCD [2, 5].

Understanding the evolving landscape of OCD treatment is crucial for clinicians and researchers. Emerging therapies offer hope for more effective management and potentially, long-term remission of symptoms. Additionally, these advancements underscore the need for personalized treatment approaches that cater to the unique neurobiological and psychological profiles of individuals with OCD [6]. Additionally, this review will explore tailored therapeutic approaches for specific populations, including pediatric patients, to provide a comprehensive overview of current and emerging OCD treatments.

Methodology

A systematic approach was utilized for this literature review, adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to gather relevant articles and studies in Emergency medicine's critical cases. A thorough search was conducted in reputable databases, including PubMed, Google Scholar, Scopus, and Web of Science, using specific keywords such as "Obsessive-Compulsive Disorder," "OCD," "cognitive-behavioral therapy," "pharmacotherapy," neuromodulation," digital interventions," "genetic research," "integrative therapies," and "pediatric OCD" to ensure comprehensive coverage of pertinent literature.

The inclusion criteria for the studies were as follows: (**1**) publications in English, (**2**) studies focusing specifically on the obsessive-compulsive disorder, and (**3**) studies reporting on trends in the treatment of it. Initially, 98 articles were retrieved from the databases. After a meticulous examination to eliminate duplicate references, 36 unique articles met the inclusion criteria. These articles underwent rigorous evaluation through a comprehensive assessment of their titles, abstracts, and full texts, confirming their alignment with the established inclusion criteria and warranting their inclusion in the review.

To provide a clear overview of the study selection process, the PRISMA flow diagram is included below [Figure 1], illustrating the number of records identified, screened, and included in the review, along with reasons for exclusion at each stage.

Traditional treatment approaches

Traditional treatment approaches for Obsessive-Compulsive Disorder (OCD) have long centered on cognitive-behavioral therapy (CBT), particularly exposure and response prevention (ERP), and pharmacological treatments, including selective serotonin reuptake inhibitors (SSRIs). CBT

and ERP are widely regarded as the most effective non-pharmacological treatments for OCD. ERP involves exposing patients to anxiety-provoking stimuli and encouraging them to resist engaging in compulsive behaviors. This method helps patients gradually reduce their anxiety and compulsions by learning that their feared outcomes are unlikely to occur [7, 8].

ERP is structured to progressively challenge individuals to face their obsessions and refrain from performing their compulsive actions. This process is methodical, starting with less distressing exposures and moving toward more anxiety-inducing situations as the patient builds tolerance. The efficacy of ERP is well-documented, with studies showing significant improvements in OCD symptoms for the majority of patients who complete the treatment program [8].

Pharmacological treatments, particularly SSRIs, have also been a cornerstone in managing OCD. SSRIs, such as fluoxetine, sertraline, and fluvoxamine, are often the first-line medications due to their effectiveness in reducing OCD symptoms by increasing serotonin levels in the brain. Other medications, including tricyclic antidepressants like clomipramine and atypical antipsychotics, are sometimes used in cases where SSRIs are not fully effective [9].

Despite their effectiveness, traditional treatment approaches have notable limitations. Not all patients respond to CBT or pharmacotherapy, and some experience significant side effects from medications. Additionally, the accessibility of qualified ERP therapists can be a barrier, as specialized training is required to administer ERP effectively [7]. Furthermore, while ERP is highly effective, it is also intensive and can be challenging for patients, leading to dropout rates that can impact treatment outcomes [8].

Advancements in psychotherapy

Advancements in psychotherapy for Obsessive-Compulsive Disorder (OCD) have led to the development of enhanced cognitive-behavioral therapy (CBT) techniques, Acceptance and Commitment Therapy (ACT), and mindfulness-based therapies. These new approaches aim to address the limitations of traditional treatments and offer more nuanced and effective interventions for individuals with OCD. Enhanced CBT techniques build upon traditional CBT and Exposure and Response Prevention (ERP) by incorporating elements such as cognitive restructuring, which helps patients identify and modify dysfunctional thoughts associated with their obsessions. This enhancement makes CBT more adaptable to individual

https://doi.org/10.25118/2763-9037.2024.v14.1309

needs and can improve its effectiveness for those who do not fully respond to standard ERP. Furthermore, integrating motivational interviewing and relapse prevention strategies into CBT has shown promise in maintaining long-term treatment gains [10].

Acceptance and Commitment Therapy (ACT) represents a "third wave" of behavioral therapies that focuses on helping individuals accept their intrusive thoughts and feelings rather than attempting to change or eliminate them. ACT encourages patients to commit to behaviors that align with their values, even in the presence of OCD-related distress. This approach helps patients develop psychological flexibility, which is crucial for managing OCD symptoms. ACT's emphasis on mindfulness and acceptance complements traditional CBT, providing a holistic approach that addresses both the cognitive and emotional aspects of OCD [6, 11].

Mindfulness-based therapies, including Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR), have gained traction as effective treatments for OCD. These therapies teach patients to cultivate a non-judgmental awareness of their thoughts and feelings, allowing them to observe their obsessions and compulsions without reacting to them. MBCT, in particular, integrates mindfulness practices with cognitive techniques to help patients manage their symptoms and reduce relapse rates. Studies have demonstrated that mindfulness-based interventions can significantly reduce OCD symptom severity and improve overall quality of life [6, 12].

These advancements in psychotherapy for OCD highlight the evolving nature of mental health treatment, emphasizing the importance of personalized and integrative approaches. By enhancing traditional CBT techniques and incorporating elements of acceptance and mindfulness, these therapies offer new avenues for effectively managing OCD, particularly for those who have not benefited from conventional treatments.

Novel pharmacological treatments

The exploration of novel pharmacological treatments for Obsessive-Compulsive Disorder (OCD) has seen promising developments, especially in the context of atypical antipsychotics, glutamate modulators, and experimental drugs such as ketamine. These advancements aim to address the limitations of traditional treatments and offer new hope for patients with treatment-resistant OCD.

https://doi.org/10.25118/2763-9037.2024.v14.1309

Atypical antipsychotics, also known as second-generation antipsychotics, have garnered attention for their potential to augment SSRIs in patients who do not respond adequately to standard treatments. Medications such as risperidone, aripiprazole, and quetiapine have shown effectiveness in reducing OCD symptoms when used in conjunction with SSRIs. These medications are generally favored over first-generation antipsychotics due to their relatively better side effect profiles and their ability to target a broader range of neurotransmitter systems involved in OCD pathology [13, 14].

Another promising area of research involves glutamate modulators. Glutamate, a major excitatory neurotransmitter in the brain, has been implicated in the pathophysiology of OCD. Drugs such as memantine, an NMDA receptor antagonist, have shown potential in reducing OCD symptoms by modulating glutamatergic neurotransmission. This represents a significant shift from the traditional focus on serotonin and offers a new avenue for treatment, particularly for patients who have not responded to SSRIs [10, 14].

Ketamine, primarily known for its anesthetic properties, has emerged as a novel treatment for OCD due to its rapid antidepressant effects. Research has indicated that low doses of ketamine can lead to significant reductions in OCD symptoms, likely through its action on glutamate pathways. This rapid onset of action is particularly beneficial for patients with severe symptoms, providing relief much faster than traditional pharmacological treatments. However, the use of ketamine is still considered experimental, and more research is needed to fully understand its efficacy and safety profile in the context of OCD [15].

Neuromodulation techniques

The field of psychiatry has witnessed significant advancements in neuromodulation techniques for treating Obsessive-Compulsive Disorder (OCD), with a focus on transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS).

Transcranial magnetic stimulation (TMS) is a noninvasive technique that uses magnetic fields to stimulate nerve cells in specific areas of the brain. It has gained FDA approval for treating OCD, particularly through devices like the BrainsWay Deep TMS system, which targets the anterior cingulate cortex and medial prefrontal cortex [16]. Studies have shown that about 45% of patients with treatment-resistant OCD experience significant

https://doi.org/10.25118/2763-9037.2024.v14.1309

symptom reduction with TMS, with some post-marketing studies reporting even higher effectiveness [7, 17]. TMS is typically administered over several weeks and is often combined with traditional therapies for enhanced efficacy.

Deep brain stimulation (DBS) involves the surgical implantation of electrodes that deliver electrical impulses to targeted brain regions. For OCD, DBS targets areas such as the subthalamic nucleus and the nucleus accumbens. DBS has shown promise in severe, treatment-resistant cases of OCD, with studies reporting improvements in symptom severity and overall functioning [18]. Despite its invasiveness, DBS offers a potential option for patients who do not respond to conventional treatments, although the procedure requires careful patient selection and postoperative management.

Vagus nerve stimulation (VNS) is another neuromodulation approach that involves stimulating the vagus nerve through an implanted device. While traditionally used for epilepsy and depression, VNS is being explored for OCD with some promising preliminary results. Research suggests that VNS can modulate brain circuits implicated in OCD, potentially offering a new avenue for treatment-resistant cases [19]. These neuromodulation techniques represent cutting-edge developments in the treatment of OCD. Each method has its own set of advantages and limitations, and ongoing research aims to optimize their efficacy and safety profiles. As these technologies evolve, they hold the potential to provide significant relief for patients struggling with severe and refractory OCD.

Digital and online interventions

The advent of digital technology has significantly expanded the treatment modalities available for obsessive-compulsive disorder (OCD), offering new avenues for therapy that extend beyond traditional face-to-face sessions. One of the most prominent digital interventions is internet-based cognitive-behavioral therapy (CBT) programs. These programs are designed to deliver structured CBT techniques through online platforms, providing greater accessibility and convenience for patients. Studies have shown that internet-based CBT can be as effective as traditional in-person therapy in reducing OCD symptoms. For instance, a stepped-care internet-delivered program demonstrated significant improvements in OCD symptoms among children and adolescents, comparable to in-person CBT [20].

Mobile applications have also emerged as valuable tools in the management of OCD. These apps offer various features, such as symptom tracking, guided self-help exercises, and access to therapeutic resources. They can serve as adjuncts to professional therapy, providing continuous support and promoting self-management skills. Apps like NOCD have gained popularity for their user-friendly interfaces and evidence-based content, which includes exposure and response prevention exercises [21].

Virtual reality (VR) exposure therapy represents another innovative approach within digital interventions for OCD. VR technology allows patients to engage in controlled and immersive exposure to feared stimuli in a virtual environment. This method provides a safe and manageable way to conduct exposure therapy, which is a core component of CBT for OCD. Early research indicates that VR exposure therapy can be an effective tool for reducing OCD symptoms, offering a novel way to engage patients who might be reluctant or unable to participate in traditional in vivo exposure exercises [22].

The integration of these digital and online interventions into standard care practices offers several advantages, including increased accessibility, flexibility, and the ability to reach a broader population. As these technologies continue to evolve and improve, they hold the potential to complement and enhance traditional therapeutic approaches, making effective OCD treatment more widely available.

Therapeutic implications of genetic and biomarker research in OCD

Recent advancements in genetic and biomarker research are significantly enhancing our understanding of Obsessive-Compulsive Disorder (OCD). Historically, the genetic basis of OCD has been recognized through family and twin studies, suggesting a strong hereditary component [23]. Recent research continues to support the idea that genetics play a critical role in the development of OCD, with approximately 50% of the risk attributed to genetic factors [24]. This genetic predisposition is thought to interact with environmental factors to trigger the disorder, highlighting the complexity of its etiology [25].

Advancements in genetic research have identified several potential genetic markers associated with OCD. For instance, variations in genes related to the serotonin system, such as those affecting serotonin transport and receptor activity, have been implicated in OCD [25]. Additionally, genes involved in the regulation of glutamate, a crucial neurotransmitter in the

https://doi.org/10.25118/2763-9037.2024.v14.1309

brain, have also been linked to OCD, providing a new avenue for understanding the neurobiological underpinnings of the disorder [23]. These discoveries are crucial for developing targeted treatments that can address the specific neurochemical imbalances in OCD patients.

Biomarkers are becoming increasingly important in predicting treatment responses and personalizing treatment strategies for OCD. Functional neuroimaging studies have identified abnormal activity in certain brain regions, such as the orbitofrontal cortex and basal ganglia, which are involved in the pathology of OCD [25]. These neuroimaging biomarkers can help in identifying individuals who are more likely to respond to specific treatments, such as selective serotonin reuptake inhibitors (SSRIs) or cognitive-behavioral therapy (CBT).

For example, a study by Stein et al. [23] found that certain patterns of brain activity could predict better outcomes with SSRIs, aiding clinicians in making more informed treatment decisions. Specific biomarkers have been identified, deepening our understanding of OCD's pathophysiology and opening new avenues for treatment. By linking these biomarkers to treatment responses, more personalized therapeutic approaches can be developed, optimizing efficacy and minimizing the trial-and-error associated with conventional treatment methods.

Furthermore, the concept of personalized medicine is gaining traction in OCD treatment. Personalized medicine aims to tailor treatment plans based on an individual's genetic makeup, biomarkers, and specific clinical features. This approach promises to improve treatment efficacy and reduce the trial-and-error period often associated with finding the right medication or therapy [23]. Ongoing research is focused on identifying additional genetic and biomarker profiles that can guide the development of personalized treatment protocols, potentially transforming the management of OCD.

Integrative and complementary therapies

The integration of complementary therapies into the treatment of Obsessive-Compulsive Disorder (OCD) has gained considerable attention due to their potential to enhance traditional treatment outcomes. Among these, nutritional and dietary supplements, exercise and physical activity, and practices such as yoga and meditation have shown promise.

https://doi.org/10.25118/2763-9037.2024.v14.1309

Nutritional and dietary supplements have been explored as adjunctive treatments for OCD. Supplements like N-acetylcysteine (NAC) have shown potential due to their antioxidant properties and role in modulating glutamate levels. A study by Jiang et al. [26] highlighted the efficacy of NAC in reducing OCD symptoms, particularly when used alongside conventional treatments. Other supplements, such as inositol, which influences serotonin pathways, have also been researched, with mixed results but promising potential for specific patient populations [27].

Exercise and physical activity are recognized for their broad mental health benefits, including reducing symptoms of anxiety and depression, which are often comorbid with OCD. Aerobic exercise, such as running and cycling, can significantly decrease OCD symptoms by increasing endorphin levels and reducing overall stress. Additionally, resistance training has been associated with improvements in both physical and mental health parameters among individuals with OCD. A review by Katz et al. [28] emphasized that structured exercise programs can lead to significant symptom reduction and improved quality of life for OCD patients.

Yoga and meditation, particularly mindfulness-based practices, have been integrated into OCD treatment protocols due to their stress-reducing and mood-enhancing effects. Yoga, which combines physical postures, breath control, and meditation, can improve mental clarity and reduce anxiety. Studies have shown that mindfulness-based cognitive therapy (MBCT), which incorporates mindfulness meditation techniques, can significantly reduce OCD symptoms by enhancing patients' ability to manage intrusive thoughts and compulsive behaviors [29].

Pediatric OCD treatments

Recognizing that OCD manifests differently across various age groups, this section focuses on the emerging trends in treating pediatric OCD. Given that early intervention is critical in this demographic, understanding these advancements is essential for improving long-term outcomes. The treatment of pediatric Obsessive-Compulsive Disorder (OCD) requires specialized approaches that address the unique needs of children and adolescents. Tailored treatment strategies are critical given the developmental differences and varying levels of insight and cooperation in younger populations.

Cognitive-behavioral therapy (CBT), particularly exposure and response prevention (ERP), is widely recognized as the first-line treatment for

https://doi.org/10.25118/2763-9037.2024.v14.1309

pediatric OCD. ERP involves gradually exposing the child to feared situations while preventing the associated compulsive behavior, thereby reducing the anxiety over time. This method has proven to be effective in both individual and family settings, emphasizing the role of parents and caregivers in supporting the child's treatment process [30].

Pharmacological treatments, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used when OCD symptoms are severe or when CBT alone is insufficient. SSRIs, such as fluoxetine and sertraline, have been shown to reduce OCD symptoms and are often prescribed in conjunction with CBT. However, the potential side effects and the necessity of monitoring make pharmacotherapy a secondary option to behavioral interventions [30].

Family-based interventions play a crucial role in treating pediatric OCD. These interventions involve educating family members about OCD and incorporating them into the therapeutic process to help manage the child's symptoms. This approach not only improves treatment outcomes but also enhances family dynamics and reduces stress associated with the disorder [31].

School-based programs are also essential, as they provide support within the child's daily environment. Such programs can include training for teachers to recognize and accommodate students with OCD, implementing behavioral strategies in the classroom, and offering resources for ongoing support. Integrating treatment within the school setting ensures that children receive continuous care and understanding, which is vital for their academic and social development [32].

Future directions and challenges

As the understanding of obsessive-compulsive disorder (OCD) continues to evolve, future research directions and associated challenges have become key areas of focus. Identifying potential new research areas, addressing ethical and accessibility considerations, and tackling challenges in implementing emerging treatments are crucial for advancing the field.

One promising research direction involves exploring the neurobiological underpinnings of OCD. Advanced neuroimaging techniques and genetic studies are shedding light on the brain circuits and genetic markers associated with the disorder. This research could pave the way for the development of more targeted and effective treatments [33]. Additionally,

https://doi.org/10.25118/2763-9037.2024.v14.1309

there is growing interest in the role of inflammation and the immune system in OCD, with studies investigating how anti-inflammatory drugs might alleviate symptoms [34].

Ethical considerations are also paramount in the development and implementation of new OCD treatments. As novel interventions, such as deep brain stimulation and other neuromodulation techniques, become more prevalent, ensuring informed consent and safeguarding patient autonomy are critical. Moreover, the use of digital and online interventions raises concerns about data privacy and the potential for misuse of sensitive patient information [35].

Accessibility is another significant challenge. Despite advances in treatment, many patients still face barriers to accessing care, including geographical limitations, financial constraints, and a shortage of specialized mental health professionals. Addressing these disparities is essential to ensure that all individuals with OCD can benefit from emerging therapies [36].

Finally, implementing emerging treatments in real-world settings presents its own set of challenges. Integrating novel interventions into existing healthcare systems requires comprehensive training for clinicians, adequate funding, and ongoing research to monitor long-term outcomes. Additionally, the heterogeneity of OCD symptoms necessitates personalized treatment approaches, which can be difficult to standardize and implement on a large scale [37].

Conclusion

In conclusion, this literature review highlights significant advancements in OCD treatment, from enhanced CBT techniques and novel pharmacological options to neuromodulation and digital interventions. These developments hold promise for more effective and individualized care, addressing both traditional limitations and treatment-resistant cases. Future research should focus on the neurobiological basis of OCD, personalized medicine approaches, and overcoming ethical and accessibility challenges. These insights are crucial for improving clinical practice and patient outcomes.

References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American Psychiatric Association; 2013. https://doi.org/10.1176/appi.books.9780890425596

2. National Institute of Mental Health. Obsessive-Compulsive Disorder (OCD). Bethesda: National Institute of Mental Health; [cited 2007 Feb 23]. https://www.nimh.nih.gov/health/statistics/obsessive-compulsive-disorder-ocd

3. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53-63. https://doi.org/10.1038/mp.2008.94 PMID:18725912 - PMCID:PMC2797569

4. Veale D, Roberts A. Obsessive-compulsive disorder. BMJ. 2014;348:g2183. https://doi.org/10.1136/bmj.g2183 PMID:24709802

5. Phillips KA, Stein DJ. Obsessive-Compulsive Disorder (OCD). [place unknown]: MSD Manual Professional Version; 2023. https://www.msdmanuals.com/professional/psychiatric-disorders/obsessive-compulsive-and-related-disorders/obsessive-compulsive-disorder-ocd

6. Burkle JJ, Fendel JC, Schmidt S. Mindfulness-based and acceptance-based programmes in the treatment of obsessive-compulsive disorder: a study protocol for a systematic review and meta-analysis. BMJ Open. 2021;11(6):e050329. https://doi.org/10.1136/bmjopen-2021-050329 PMID:34172553 - PMCID:PMC8237723

7. International OCD Foundation. Transcranial Magnetic Stimulation (TMS) for OCD. Boston: International OCD Foundation; c2024. https://iocdf.org/about-ocd/treatment/tms/

8. Kelly, O. OCD medications: how antidepressants and antipsychotics can help. New York: Verywell Mind; 2024. https://www.verywellmind.com/medications-to-treat-ocd-2510644

9. Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, Rapinesi C, Sani G, Girardi P, Kotzalidis GD, Pompili M. Psychopharmacological treatment of obsessive-compulsive disorder (OCD). Curr Neuropharmacol. 2019;17(8):710-36. https://doi.org/10.2174/1570159x16666180813155017 PMID:30101713 - PMCID:PMC7059159.

10. Finch R, Vargas BE. We tried 100+ therapy services and apps- and we recommend these 8 for online CBT. New York: Verywell Mind; 2024. https://www.verywellmind.com/online-cbt-therapy-7371586

11. Akhouri D, Hamza, Kumar S, Reyazuddin M. Acceptance and commitment therapy as an add-on treatment for the management of patients with obsessive-compulsive disorder. Ind Psychiatry J. 2023;32(Suppl 1):S179-85. https://doi.org/10.4103/ipj.ipj_213_23 PMID:38370965 - PMCID:PMC10871435

12. Olivine A. What is mindfulness therapy? Mindfulness-based cognitive behavioral therapy and cognitive therapy, MBCBT, MBCT. New York: Verywell Health; 2024. https://www.verywellhealth.com/mindfulness-therapy-5212796

13. Bommarito S, Morris M. The role of antipsychotics in OCD. Silver Spring: Anxiety and Depression Association of America; 2023. https://adaa.org/learn-from-us/from-the-experts/blog-posts/professional/role-antipsychotics-ocd

14. Huang Y, Weng Y, Lan L, Zhu C, Shen T, Tang W, Lai HY. Insight in obsessive-compulsive disorder: conception, clinical characteristics, neuroimaging, and treatment. Psychoradiology. 2023;3:kkad025. https://doi.org/10.1093/psyrad/kkad025 PMID:38666121 - PMCID:PMC10917385

15. Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: a registered report protocol. PLoS One. 2022;17(6):e0269772.

https://doi.org/10.1371/journal.pone.0269772 PMID:35709149 PMCID:PMC9202921

16. Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. Silver Spring: Food and Drug Administration; 2018. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder

17. Tendler A, Blackman S. Achieving OCD relief: consideration of TMS earlier in the treatment continuum. Cranbury: Psychiatric Times; 2023. https://www.psychiatrictimes.com/view/achieving-ocd-relief-consideration-of-tms-earlier-in-the-treatment-continuum

18. Karas PJ, Lee S, Jimenez-Shahed J, Goodman WK, Viswanathan A, Sheth SA. Deep brain stimulation for obsessive compulsive disorder: evolution of surgical stimulation target parallels changing model of dysfunctional brain circuits. Front Neurosci. 2019;12:998. https://doi.org/10.3389/fnins.2018.00998 PMID:30670945 - PMCID:PMC6331476

19. Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev. 2005;29(3):493-500. https://doi.org/10.1016/j.neubiorev.2005.01.004 PMID:15820552

20. Aspvall K, Andersson E, Melin K, Norlin L, Eriksson V, Vigerland S, Jolstedt M, Silverberg-Morse M, Wallin L, Sampaio F, Feldman I, Bottai M, Lenhard F, Mataix-Cols D, Serlachius E. Effect of an internet-delivered stepped-care program vs in-person cognitive behavioral therapy on obsessive-compulsive disorder symptoms in children and adolescents: a randomized clinical trial. JAMA. 2021;325(18):1863-73. https://doi.org/10.1001/jama.2021.3839 PMID:33974020 - PMCID:PMC8114140

21. McGrath P. Can exercise help with OCD? Chicago: NOCD; 2021. https://www.treatmyocd.com/blog/can-exercise-help-with-ocd

22. Hedman E, Furmark T, Carlbring P, Ljotsson B, Ruck C, Lindefors N, Andersson G. A 5-Year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res.

2011;13(2):e39. https://doi.org/10.2196/jmir.1776 PMID:21676694 - PMCID:PMC3221374

23. Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, van den Heuvel OA, Simpson HB. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52. https://doi.org/10.1038/s41572-019-0102-3 PMID:31371720 PMCID:PMC7370844

24. Mahjani B, Bey K, Boberg J, Burton C. Genetics of obsessive-compulsive disorder. Psychol Med. 2021;51(13):2247-59. https://doi.org/10.1017/s0033291721001744 PMID:34030745 PMCID:PMC8477226

25. Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15(6):410-24. https://doi.org/10.1038/nrn3746 PMID:24840803

26. Jiang C, Zou J, Lv Q, Yang Y. Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Palliat Med. 2021;10(6):6564-76. https://doi.org/10.21037/apm-21-1138 PMID:34237968

27. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996;153(9):1219-21. https://doi.org/10.1176/ajp.153.9.1219 PMID:8780431

28. Katz DE, Rector NA, McCabe RE, Hawley LL, Rowa K, Richter MA, Ornstein T, Regev R, McKinnon M, Laposa JM. The effect of aerobic exercise alone and in combination with cognitive behavioural therapy on obsessive compulsive disorder: a randomized control study. J Anxiety Disord. 2023;98:102746. https://doi.org/10.1016/j.janxdis.2023.102746 PMID:37494756

29. Didonna F, Lanfredi M, Xodo E, Ferrari C, Rossi R, Pedrini L. Mindfulness-based cognitive therapy for obsessive-compulsive disorder: a pilot study. J Psychiatr Pract. 2019;25(2):156-70. https://doi.org/10.1097/pra.0000000000000377 PMID:30849066

30. Cervin M. [Podcast] Which Treatments Work for Pediatric OCD? Efficacy and Acceptability of CBT and Serotonin Reuptake Inhibitors. London: ACAMH; 2024. [33 min., 56 sec]. https://www.acamh.org/podcasts/which-treatments-work-for-pediatric-ocd/

31. Peris TS, Thamrin H, Rozenman MS. Family intervention for child and adolescent anxiety: a meta-analytic review of therapy targets, techniques, and outcomes. J Affect Disord. 2021;286:282-95. https://doi.org/10.1016/j.jad.2021.02.053 PMID:33756306

32. Angelosante A, Colognori D, Goldstein CR, Warner CM. School-based interventions for anxiety in youth. In: McKay D, Storch E, editors. Handbook of child and adolescent anxiety disorders. New York: Springer; 2011. https://doi.org/10.1007/978-1-4419-7784-7_28

33. Fineberg NA, Hollander E, Pallanti S, Walitza S, Grunblatt E, Dell'Osso BM, Albert U, Geller DA, Brakoulias V, Janardhan Reddy YC, Arumugham SS, Shavitt RG, Drummond L, Grancini B, De Carlo V, Cinosi E, Chamberlain SR, Ioannidis K, Rodriguez CI, Garg K, Castle D, Van Ameringen M, Stein DJ, Carmi L, Zohar J, Menchon JM. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol. 2020;35(4):173-93. https://doi.org/10.1097/yic.0000000000000314 PMID:32433254 PMCID:PMC7255490

34. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317(13):1358-67. https://doi.org/10.1001/jama.2017.2200 PMID:28384832

35. Simpson HB, Rynn MA. OCD: current research and future directions. Cranbury: Psychiatric Times; 2015. https://www.psychiatrictimes.com/view/ocd-current-research-and-future-directions

36. Ioannidis K, Chamberlain SR, Treder MS, Kiraly F, Leppink EW, Redden SA, Stein DJ, Lochner C, Grant JE. Problematic internet use (PIU): associations with the impulsive-compulsive spectrum. An application of machine learning in psychiatry. J Psychiatr Res.

2016;83:94-102. https://doi.org/10.1016/j.jpsychires.2016.08.010 PMID:27580487 - PMCID:PMC5119576

37. Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry. 2010;71(6):784-92. https://doi.org/10.4088/jcp.09m05911blu PMID:20492845



Figure 1. Iillustrates the PRISMA flow diagram